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Abstract 
Purpose:  
 
With the increasing prevalence of diabetes, annual screening for diabetic retinopathy (DR) by expert human 
grading of retinal images is challenging. Automated DR image assessment systems (ARIAS) of retinal images 
may provide clinically and costeffective detection of retinopathy but to date the independent validity of ARIAS, 
and clinical applicability of different commercially available ARIAS to ‘real life’ screening has not been evaluated. 
The purpose of this study was determine if available ARIAS can safely be introduced into DR screening pathways 
and replace human graders. 
 
Setting:  
 
Consecutive patients with a diagnosis of diabetes mellitus, who attended their annual visit at their NHS Diabetes 
Eye Screening Programme in London. 
 
Methods:  
 
Retinal images from 20,258 consecutive patients attending routine annual diabetic eye check between 1st June 
2012 and 4th November 2013. Retinal images were manually graded following a standard national protocol for 
DR screening and were processed by three ARIAS: iGradingM, Retmarker, and EyeArt. Discrepancies between 
manual grades and ARIAS were sent for arbitration to a reading center. Screening performance (sensitivity, false 
positive rate, likelihood ratios), and diagnostic accuracy (95% confidence intervals of screening performance 
measures) were determined. Secondary analysis explored the influence of patients’ ethnicity, age, gender and 
camera on screening performance. Economic analysis estimated the cost per appropriate screening outcome. 
 
Results:  
 
Sensitivity point estimates (95% confidence interval) of the ARIAS were as follows: EyeArt 94.7% (94.295.2) for 
any retinopathy, 93.8% (92.994.6) for referable retinopathy (human graded as either ungradable, maculopathy, 
preproliferative or proliferative) 99.6% (97.099.9) for proliferative retinopathy; Retmarker 73.0% (72.074.0) for 
any retinopathy, 85.0% (83.686.2) for referable retinopathy 97.9% (94.999.1) for proliferative retinopathy. 
iGradingM classified all images as either having disease or being ungradeable. EyeArt and Retmarker were cost 
saving compared to manual grading both as a replacement for initial human grading, or as a filter prior to 
primary human grading, although the latter approach was less costeffective 
 
Conclusions:  
 
Retmarker and EyeArt achieved acceptable sensitivity for referable retinopathy when compared with human 
graders and had sufficient specificity to make them costeffective alternatives to manual grading alone. ARIAS 
have the potential to reduce costs in developed world healthcare economies and to aid delivery of DR screening 
in developing or remote healthcare settings. 
 
